LOGIN  |  REGISTER
Cue Biopharma

Health Catalyst to Participate in Upcoming Investor Conferences

March 04, 2024 | Last Trade: US$6.89 0.47 -6.39

SALT LAKE CITY, March 04, 2024 (GLOBE NEWSWIRE) -- Health Catalyst, Inc. ("Health Catalyst", Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare organizations, today announced that members of leadership will participate in the following upcoming investor conferences:

  • The Raymond James 45th Annual Institutional Investors Conference, being held in Orlando, including a fireside chat with Jason Alger, Chief Financial Officer, and Adam Brown, Senior Vice President of FP&A and Investor Relations, on Wednesday, March 6, 2024 at 11:00am ET.
  • The Barclays 26th Annual Global Healthcare Conference, being held in Miami, including a fireside chat with Dan Burton, Chief Executive Officer, and Jason Alger, Chief Financial Officer, on Thursday, March 14, 2024 at 10:15am ET. The webcast link and related presentation materials will be available online at https://ir.healthcatalyst.com.

About Health Catalyst

Health Catalyst is a leading provider of data and analytics technology and services to healthcare organizations committed to being the catalyst for massive, measurable, data-informed healthcare improvement. Its customers leverage the cloud-based data platform—powered by data from more than 100 million patient records and encompassing trillions of facts—as well as its analytics software and professional services expertise to make data-informed decisions and realize measurable clinical, financial, and operational improvements. Health Catalyst envisions a future in which all healthcare decisions are data informed.

Health Catalyst Investor Relations Contact:

Adam Brown
Senior Vice President, Investor Relations and FP&A
+1 (855)-309-6800
This email address is being protected from spambots. You need JavaScript enabled to view it.

Health Catalyst Media Contact:

Tarah Neujahr Bryan
Chief Marketing Officer
This email address is being protected from spambots. You need JavaScript enabled to view it.

Assertio

Stock Quote

Featured Stock

Cue Biopharma

Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...

CLICK TO LEARN MORE

Featured Stock

Astria Therapeutics

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page